Epcoritamab + Prednisone + Rituximab + Lenalidomide + Doxorubicin + Vincristine + Cyclophosphamide + Obinutuzumab + Bendamustine
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Follicular Lymphoma (FL)
Conditions
Follicular Lymphoma (FL)
Trial Timeline
Feb 5, 2024 → Nov 1, 2037
NCT ID
NCT06191744About Epcoritamab + Prednisone + Rituximab + Lenalidomide + Doxorubicin + Vincristine + Cyclophosphamide + Obinutuzumab + Bendamustine
Epcoritamab + Prednisone + Rituximab + Lenalidomide + Doxorubicin + Vincristine + Cyclophosphamide + Obinutuzumab + Bendamustine is a phase 3 stage product being developed by AbbVie for Follicular Lymphoma (FL). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06191744. Target conditions include Follicular Lymphoma (FL).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06191744 | Phase 3 | Recruiting |
Competing Products
20 competing products in Follicular Lymphoma (FL)